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Abstract
Background: The occurrence of familial forms of sarcoidosis (OMIM 181100) suggests a genetic predisposition. The
involvement of butyrophilin-like 2 (BTNL2) gene (rs2076530 variant) has to be investigated.
Results: The study performed independent analyses of BTNL2 polymorphism, clinical phenotypes, and outcomes in
familial vs. sporadic presentations in 256 sporadic and 207 familial cases from 140 families. The logistic multivariate
model showed that a young age at diagnosis and the combination of lung and skin involvement at diagnosis may
distinguish sporadic from familial sarcoidosis (p = 0.016 and p = 0.041). We observed also that Sarcoid Clinical Activity
Classification (SCAC) profiles were significantly different between familial and sporadic cases (p = 0.0497).
Variant rs2076530 was more frequent in patients than in controls (OR = 2.02; 95% CI: [1.32–3.09]) but showed no
difference between sporadic and familial cases and no difference according to the clinical phenotype or the outcome.
Conclusion: Despite a significant difference in BTNL2 polymorphism between sarcoid patients and controls, there was
no such difference between familial and sporadic sarcoidosis cases and no correlation between BTNL2 polymorphism
and disease severity or outcome. Thus, BTNL2 difference cannot be considered as a key marker for disease classification
or patient management.
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Background
Sarcoidosis is a rare multisystemic granulomatous dis-
order of still unknown origin. It has various presenta-
tions, severities, treatments, and outcomes [1]. Genetic
studies have searched for polymorphisms associated with
the risk of developing the disease and for genotype-
phenotype correlations. Among several candidate genes,
BTNL2 (butyrophylin-like 2) has been intensively stud-
ied. A recent meta-analysis has confirmed that BTNL2
rs2076530 polymorphism contributes to the risk of
sarcoidosis [2]. Meanwhile, it has been difficult to
investigate the clinical phenotypes and outcomes of sar-
coidosis in search for genotype-phenotype correlations.
Nevertheless, interesting suggestions about classical radio-
graphic staging [3], factor analysis [4, 5], SCAC (Sarcoid
Clinical Activity Classification) [6], and WASOG (World
Association for Sarcoidosis and Other Granulomatous
Disorders) clinical outcome status classification [7] are
available.
We investigated BTNL2 gene in familial forms of sar-
coidosis to assess the role of this gene as a major indica-
tor of hereditary predisposition to the disease [8–10]
and find out whether it can be a useful genetic marker
for clinical management and prognosis.* Correspondence: yves.pacheco@univ-lyon1.fr
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SARCFAM (a national project on familial sarcoidosis) is
a prospective observational cohort study started in 2008.
It involves 28 French university departments of internal
medicine or pulmonology that care for sarcoidosis
patients.
Three inclusion criteria were: i) clinical and paraclinical
features consistent with sarcoidosis; ii) histopathological
evidence of non-caseating granuloma, except Löfgren syn-
drome; and, iii) exclusion of any other chronic disease.
The evidence for non-caseating granulomatous lesions
was obtained by mediastinoscopy (26.4%), or bronchial/
pulmonary (34.9%), accessory salivary gland (12.3%), per-
ipheral lymph node (10.4%), skin (9.8%), conjunctiva
(2.5%), kidney (1.2%) or other (2.5%) biopsies.
All 463 cases included were diagnosed according to
the Joint Statement of the American Thoracic Society
(ATS), the European Respiratory Society (ERS), and the
(WASOG) [11]. The disease type (familial vs. sporadic)
was determined by structured interview.
The control population for the genetic investigation
consisted of 430 DNA samples from a single genetic
database of healthy human reference population. The
mean age (41.5 ± 17.5 years) and geographic origins
[European: n = 324 (75.3%) and Sub-Saharan African
plus Caribbean: n = 106 (24.7%)] were quite similar to
those of the study sarcoid patients.
Clinical assessment
All patients with sporadic sarcoidosis or index cases with
familial sarcoidosis were diagnosed and followed-up in
the 28 clinical centers. A specific case report form was
filled in with demographic data, medical history, disease
onset (symptomatic or asymptomatic), detailed organ in-
volvement, treatments, and outcome. A detailed familial
history of sarcoidosis was also examined to assess gen-
etic predisposition. Familial cases were offered a DNA
sampling and the related forms were filled in the center
where the index case was diagnosed.
Clinical, biological, and imaging data were also collected
at diagnosis and each follow-up visit until December 2012.
These data included: i) chest X-ray staging (0: no involve-
ment, 1: isolated hilar lymphadenopathy, 2: hilar lymphaden-
opathy with pulmonary infiltration, 3: isolated pulmonary
infiltration without fibrosis, 4: pulmonary fibrosis); ii)
pulmonary function testing: forced expiratory volume
in one second (FEV1), forced vital capacity (FVC),
FEV1/FVC ratio, and total lung capacity (TLC); iii)
biological variables: serum calcium and creatinine,
bronchoalveolar lavage cell count; and, iv) information
about treatment: systemic treatment with corticoste-
roids or non-steroid immunosuppressive agents.
The disease outcome was examined using SCAC with
six progression patterns [6] and, whenever possible, a
classification of outcome in four categories: 1) recovery
within 3 years; 2) recovery between 3 and 5 years; 3) no
recovery at 5 years; 4) death.
Genetic study
Blood DNAs were obtained from nearly all patients and
tested for BTNL2 gene rs2076530 polymorphism. Primer
oligonucleotides for polymerase chain reaction and DNA
sequencing were located within the reference sequence
surrounding rs2076530, the major single-nucleotide
polymorphisms (SNPs) that induce truncation of the
BTNL2 protein [8]. A 490-bp amplicon was produced
and sequenced using primers 5′-AATGCACAGAGC
ATGGAGGTGAG-3′ and 5′-GAAGATACTGGAAAAG
ATACAAG-3′.
The quality control of PCR products was performed on
a LabChipGX system (PERKIN ELMER™) and the prod-
ucts purified by NucleoFast® 96 PCR Clean-up Kit from
MACHEREY-NAGEL™. The sequencing was performed
by Big Dye terminator v1.1 after purification with BigDye®
XTerminator™ Purification Kit. Sequence delineation and
base calling used an automated fluorescent DNA sequen-
cer (Applied Biosystems™, model 3130xl).
Statistical analysis
Familial and sporadic cases were compared using a gen-
eralized linear mixed model. To allow for family links,
the model included correlations between patients’ ran-
dom effects [12].
In a first application of the model, univariate submo-
dels were constructed and compared with a null model
(model with intercept only) using a likelihood ratio test
to test the effects of the main variables (Table 1). The
clinical characteristics of BTNL2 G/G vs. BTNL2 A/A
plus BTNL2 A/G genotypes were compared with the
same method (Table 2). Because the study was mainly
exploratory, only raw p-values are shown; however, a
Bonferroni correction for multiple testing was applied and
when raw p-values were significant, adjusted p-values
were also calculated [13].
In another application, a multivariate model was
built with the most important variables collected at
diagnosis (age, sex, organs involved, chest X-ray stage,




Among the 463 patients, 256 presented with a sporadic
disease and 207 belonged to 140 families (one patient
from each of 85 families, two patients from each of 48
families, three patients from each of five families, four
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Table 1 Epidemiological, clinical, and biological characteristics of familial and sporadic sarcoid patients
Data Number Familial cases Sporadic cases Univariate model raw p value* Multivariate model p value
Epidemiological data
N 463 207 (44.7%) 256 (55.3%)
Sex 463 0.49
Male 201 86 (41.6%) 115 (44.9%) 0.20
Female 262 121 (58.4%) 141 (55.1%) Ref.
Age at diagnosis 424 0.001 [0.021] 0.016
Mean ± SD 38.2 ± 13.1 43.0 ± 15.5
Median [q1; q3] 35.5 [29.3; 46.2] 40.3 [30.6; 54.0]
Ethnicity 303 0.85
European 235 112 (77.2%) 123 (77.9%)
Caribbean or Sub-Saharan African 68 33 (22.8%) 35 (22.1%)
Smokers 381 0.43
Yes 156 56 (38.4%) 100 (42.6%)
No 225 90 (61.6%) 135 (57.4%)
Clinical data at diagnosis
Disease onset 401 0.015 [0.28]
Asymptomatic 137 45 (27.3%) 92 (39.0%)
Symptomatic 264 120 (72.7%) 144 (61.0%)
Löfgren syndrome 378 0.26
Yes 58 29 (17.8%) 29 (13.5%)
No 320 134 (82.2%) 186 (86.5%)
Number of organs involved 414 0.144
1 158 69 (39.9%) 89 (36.9%)
2 117 36 (20.8%) 81 (33.6%)
3 70 29 (16.8%) 41 (17.0%)
≥ 4 69 39 (22.5%) 30 (12.5%)
Organs involved 414 <0.001 [0.003]
Lungs only 148 68 (39.31%) 80 (33.2%) 0.65
Lungs and Eyes 53 10 (5.78%) 43 (17.84%) 0.076
Lungs and Skin 21 15 (8.67%) 6 (2.49%) 0.041
Other organs 192 80 (46.24%) 112 (46.47%) Ref
X-ray staging 456 0.20 0.78
0 68 40 (19.8%) 28 (11.0%)
1 162 66 (32.7%) 96 (37.8%)
2 157 69 (34.2%) 88 (34.7%)
3 48 15 (7.4%) 33 (13.0%)
4 21 12 (5.9%) 9 (3.5%)
PFT at first visit
TLC (%) 215 0.93
< 80% 47 18 (22.2%) 29 (21.6%)
≥ 80% 168 63 (77.8%) 105 (78.4%)
FEV1/FVC 242 0.43
< 70% 55 18 (20.0%) 37 (24.3%)
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patients from one family, and seven patients from an-
other one). Most of the 303 patients with known ances-
tors’ birth countries were European (78%); the others
were Caribbean or Sub-Saharan African (22%). This dis-
tribution did not differ from that of the controls. Table 1
shows a comparison of patient epidemiological, clinical,
and biological characteristics between sporadic and
familial cases.
Impact of disease type
Univariate comparisons between sporadic and familial
cases revealed no significant differences in terms of sex
ratio, geographical origin, number of involved organs at
diagnosis, distribution of chest X-ray stages at diagnosis,
respiratory function tests, biological data, or smoking
habits. Also, the incidence of Löfgren syndrome was not
different between familial and sporadic cases (17.8% vs.
Table 1 Epidemiological, clinical, and biological characteristics of familial and sporadic sarcoid patients (Continued)
≥ 70% 187 72 (80.0%) 115 (75.7%)
Biology at first visit
Bronchoalveolar lavage lymphocytes (%) 95 0.171
< 10 23 3 (11.6%) 20 (29.0%)
[10; 20] 17 5 (19.2%) 12 (17.4%)
> 20 55 18 (69.2%) 37 (53.6%)
Calcemia 256 0.80
< 2.25 52 21 (22.6%) 31 (19.0%)
[2.25 - 2.5] 182 64 (68.8%) 118 (72.4%)
> 2.5 22 8 (8.6%) 14 (8.6%)
Treatment
Treatment 463 <0.001 [0.008]
None 136 79 (38.2%) 57 (22.3%)
At least one 327 128 (61.8%) 199 (77.7%)
Type of treatment 327 0.188
Corticosteroids only 186 67 (52.3%) 119 (59.8%)
Other treatment 141 61 (47.7%) 80 (40.2%)
Pattern of disease course
SCAC 414 0.003 [0.0497]
1- symptomatic - no treatment 48 30 (18.1%) 18 (7.3%)
2- symptomatic - treatment≤ 12 mo. 47 18 (10.8%) 29 (11.7%)
3- symptomatic - treatment > 12 mo. 172 72 (43.4%) 100 (40.3%)
4- asymptomatic - no treatment 51 19 (11.5%) 32 (12.9%)
5- asymptomatic - treatment≤ 12 mo. 16 7 (4.2%) 9 (3.6%)
6- asymptomatic - treatment > 12 mo. 80 20 (12.0%) 60 (24.2%)
Classification of outcome 138 0.165**
1- recovery within 3 years 72 24 (57.14%) 48 (50%)
2- recovery between 3 and 5 years 32 6 (14.29%) 26 (27.08%)
3- no recovery at 5 years 30 12 (28.57%) 18 (18.75%)
4- death 4 0 (0%) 4 (4.17%)
Genetic data
BTNL2 436 0.17*** 0.39***
BTNL2 A/A 201 89 (47.8%) 112 (44.8%)
BTNL2 A/G 194 84 (45.2%) 110 (44.0%)
BTNL2 G/G 41 13 (7.0%) 28 (11.2%)
*Significant raw p-values are followed by corrected p-values (Bonferroni correction) in brackets
**Small “Death” category excluded
***G/G vs. G/A + A/A
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Table 2 Comparison of clinical characteristics according to the BTLN2 genotype (G/G vs. A/A plus G/A)




European 226 103 (75.7%) 104 (80%) 19 (73.1%)
Caribbean or Sub-Saharan African 66 33 (24.3%) 26 (20%) 7 (26.9%)
Clinical data at diagnosis
Disease onset 389 0.91
Asymptomatic 130 60 (34.29%) 59 (33.15%) 11 (30.56%)
Symptomatic 259 115 (65.71%) 119 (66.85%) 25 (69.44%)
Löfgren syndrome 368 0.042 [0.42]
Yes 58 25 (14.71%) 32 (19.39%) 1 (3.03%)
No 310 145 (85.29%) 133 (80.61%) 32 (96.97%)
Number of organs involved 397 0.074
1 152 70 (38.46%) 73 (41.01%) 9 (24.32%)
2 115 55 (30.22%) 49 (27.53%) 11 (29.73%)
3 66 29 (15.93%) 33 (18.54%) 4 (10.81%)
≥ 4 64 28 (15.39%) 23 (12.92%) 13 (35.14%)
Organs involved 397 0.082
Lungs only 143 68 (37.36%) 67 (37.64%) 8 (21.62%)
Lungs and Eyes 52 23 (12.64%) 20 (11.24%) 9 (24.33%)
Lungs and Skin 20 11 (6.04%) 8 (4.49%) 1 (2.7%)
Other sites 182 80 (43.96%) 83 (46.63%) 19 (51.35%)
X-ray staging 432 0.26
0 57 25 (12.5%) 26 (13.47%) 6 (15.38%)
1 158 77 (38.5%) 65 (33.68%) 16 (41.03%)
2 149 67 (33.5%) 68 (35.23%) 14 (35.9%)
3 47 24 (12%) 22 (11.4%) 1 (2.56%)
4 21 7 (3.5%) 12 (6.22%) 2 (5.13%)
PFT at first visit
TLC (%) 0.098
< 80% 47 23 (24.47%) 22 (23.91%) 2 (9.52%)
≥ 80% 160 71 (75.53%) 70 (76.09%) 19 (90.48%)
Pattern of disease course
SCAC 398 0.83
1- symptomatic - no treatment 46 21 (11.6%) 22 (12.1%) 3 (8.3%)
2- symptomatic - treatment ≤ 12 mo. 47 19 (10.5%) 22 (12.1%) 6 (16.7%)
3- symptomatic - treatment > 12 mo. 166 75 (41.4%) 74 (40.9%) 17 (47.2%)
4- asymptomatic - no treatment 48 19 (10.5%) 26 (14.4%) 3 (8.3%)
5- asymptomatic - treatment ≤ 12 mo. 14 6 (3.3%) 7 (3.9%) 1 (2.8%)
6- asymptomatic - treatment > 12 mo. 77 41 (22.7%) 30 (16.6%) 6 (16.7%)
Classification of outcome 137 0.015 [0.14]***
1- recovery within 3 years 72 29 (52.73%) 36 (52.17%) 7 (53.85%)
2- recovery between 3 and 5 years 32 9 (16.36%) 17 (24.64%) 6 (46.15%)
3- no recovery at 5 years 29 15 (27.27%) 14 (20.29%) 0 (0%)
4- death 4 2 (3.64%) 2 (2.9%) 0 (0%)
*Significant raw p-values are followed by corrected p-values (Bonferroni correction) in brackets
**Small “Death” category excluded
***G/G vs. G/A + A/A
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13.5%, respectively). However, the age at diagnosis was
lower in familial cases (p = 0.021 after Bonferroni correc-
tion) and the combinations of organs involved at diagno-
sis were significantly different (p = 0.003 after Bonferroni
correction).
Sporadic cases needed treatment more often than famil-
ial cases (p = 0.008 after Bonferroni correction). Among
treated patients, 52.3% of familial and 59.8% of sporadic
cases received exclusively corticosteroids. Other treat-
ments (methotrexate, azathioprine, aminoquinolines, or
anti-TNF alpha) were given to 47.7% of familial and 40.2%
of sporadic cases. The SCAC was significantly different
between familial and sporadic cases (p = 0.0497 after
Bonferroni correction) but the classification of outcome
did not show a significant difference.
A multivariate model was then constructed with the
following variables assessed at diagnosis: age, sex, chest
X-ray stage, organs involved, and BTNL2 polymorphism.
The model was run on the 390 patients without missing
data (233 sporadic and 157 familial cases, the former be-
ing the reference). The OR estimates and their 95% CIs
were 0.81 [0.69; 0.96] for age (per ten-year increment)
and 0.73 [0.45; 1.18] for sex (males vs. females). Consider-
ing an additive effect for ordinal variables and a dominant
genetic model for BTNL2 polymorphism (GG being the
wild-type homozygous genotype), the OR estimates were:
1.04 [0.80; 1.34] for chest X-ray stage (per stage incre-
ment), 1.46 [0.62; 3.45] for BTNL2 (G/G vs. G/A plus A/
A), 1.13 [0.67; 1.88] for organs involved “lungs only”, 0.47
[0.21; 1.08] for “lungs and eyes”, 3.16 [1.05; 9.54] for “lungs
and skin” (“other organs” being the reference). In
agreement with the univariate analyses, familial cases
were significantly younger at diagnosis than sporadic
ones (p = 0.016) and the organs involved in familial
cases were more often “lungs and skin” (p = 0.041).
Impact of BTNL2
In the control population (n = 430), the genotypes observed
for SNP rs2076530 (normal allele vs. mutated variant A)
were respectively 75 (17.4%) G/G, 143 (33.2%) G/A, and
212 (49.3%) A/A. The relative distribution of genotype G/G
vs. G/A plus A/A was significantly different between
sarcoidosis cases and the control population (odds ratio,
OR = 2.02; 95% confidence interval, CI: [1.32–3.09]). The
same comparison performed between familial and sporadic
cases showed no statistically significant difference.
Table 2 shows that, in the whole population of patients,
there is no correlation between BTNL2 polymorphism
and the various clinical phenotypes, the SCAC, or the
classification of outcome.
Discussion
The present study was based on clinical and genetic in-
vestigations in a nation-wide cohort of both familial and
sporadic sarcoidosis cases. Comparisons between familial
and sporadic cases showed some clinical differences but,
mostly, the absence of difference in BTNL2 rs2076530
variant frequency. Moreover, the study found no
genotype-phenotype correlation between BTNL2 and clin-
ical phenotype, SCAC, or the classification of outcome.
Familial aggregation of sarcoidosis cases is already well
known [14]; it raised the issues of predisposing genes
and genotypes involved in a Mendelian inheritance of
the clinical phenotype. Along with ACCESS [15], we
assessed the clinical phenotypes and the outcomes in a
large cohort of sarcoid patients comparing sporadic and
familial cases. In agreement with the literature [16–19],
we observed no difference in sex ratio or geographic
origin between familial and sporadic cases. However, in
contrast with other reports [16, 18, 19], age at diagnosis
was significantly lower in the present study familial
cases. This observation suggests that diagnosing sarcoid-
osis in individuals closely related to index cases in pre-
disposed families may be made earlier than in sporadic
cases. A previous work [17] compared the clinical pro-
files of patients whose diagnosis was made incidentally
with symptomatic cases but could not conclude because
of small sample sizes. In agreement with Sharma et al.
[6], we found a difference between familial and sporadic
cases regarding the disease onset (symptomatic vs. asymp-
tomatic); this difference was statistically significant as per
the raw p value but not significant after Bonferroni
correction.
In addition, in agreement with other studies [16, 17],
we found no differences in terms of chest X-ray staging
or number of organs involved at diagnosis between
familial and sporadic cases but the combinations of or-
gans involved at diagnosis was significantly different
between the two groups in univariate analyses. Also, the
multivariate analysis showed a significant difference be-
tween familial and sporadic cases regarding lungs and skin
combination. According to Delaveri et al. [20] such an ob-
servation may be in relation with the genetic predisposing
background. Finally, as also reported by Sharma et al. [16],
familial and sporadic cases did not differ in terms of drugs
used (corticosteroids alone vs. immunosuppressive drugs).
Several investigators have designed comprehensive
scoring systems to assess the disease impact and out-
come [3–8]. Two of them have integrated the need for
more than a 12-month treatment period [4, 6]. In the
present study, we found a significant difference between
familial and sporadic cases in terms of disease progres-
sion patterns (as per the SCAC) [6] but only a trend
toward a difference in the classification of outcome clas-
sification according to the duration of the disease. This
may reflect a lack of power regarding the classification
of outcome. Indeed, only 138 patients had a sufficient
follow-up to be correctly classified, whereas 344 patients
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could be classified with SCAC. A retrospective study of pa-
tients with an isolated lung involvement and 6–144
months of follow-up [5] has identified four disease pheno-
types. We cannot easily refer to this series because of the
predominance, in our series, of a multi-organ involvement.
The BTNL2-related OR we found here is similar to pre-
viously reported ones [2, 8–10]. However, our study adds
the original findings that although BTNL2 polymorphism
was strongly associated with the disease, its presence was
not predictive of the development of a rather familial or
rather sporadic case and not associated with the clinical
phenotypes, the SCAC, or the outcome. This result differs
from others that suggested that BTNL2 might be a pre-
disposing factor for persistent or progressive sarcoid-
osis [10, 21, 22]. Our data may be interpreted in the
light of the low OR of BTNL2 rs2076530 (=2) we found;
that is, the BTNL2 gene is not an explanatory factor of
disease inheritance. The role of the rs2076530 variant is
probably part of a set of genetic and environmental factors
associated with the risk of acquiring the disease.
Combined effects of HLA-DRB1/DBP1 haplotypes and
the BTNL2 variant have been previously reported [23, 24].
Here, we cannot exclude that the BTNL2-sarcoidosis asso-
ciation we observed is the consequence of gene proximity
in the 6p21 area with a synergistic effect of some HLA
class II haplotypes and the truncated form of BTNL2 on
T-cell activation and proliferation process [22, 25]. Actu-
ally, one limitation of the present study is the lack of ex-
tensive screening for HLA-DRB1/DPB1 in the patients. In
familial cases, we have checked for SNPs within the HLA-
DRB1/DPB1 genes in 9 unrelated index cases of familial
sarcoidosis and found no common genotypes; this sug-
gests that these index cases do not have a common ances-
tor and that there is no founder effect. We have also
screened the full sequence of BTNL2 in a subset of 40 pa-
tients from 40 families and found no other variants than
those described in the last version of the NCBI dbSNP
database. Actually, we analysed the BTNL2 gene for other
variants and found that the rs2076530 A/A variant geno-
type cosegregates with the rs2076520 synonymous V313V,
rs28362679 missense S334L, and rs41441651 missense
D336N polymorphisms and, to date, we cannot exclude
that these polymorphisms may have a complementary role
with that of rs2076530 in the malfunction of BTNL2.
Taken together these data demonstrate clearly that, with
an OR = 2.0, the rs2076530 splicing variant of BTNL2
should be considered as a genetic risk factor for sarcoid-
osis but cannot be considered as a major gene explaining
a Mendelian inheritance in the familial form of the dis-
ease. As others, we suggest strongly that BTNL2 screening
belongs to the panel of biomarkers in the diagnosis of
sarcoidosis together with HLA class II haplotyping and
further coming genes. Despite conflicting opinions, the
6p21.3 region carrying HLA and BTNL2 genes is still
considered to be associated with an increased risk of
TH1/TH17 diseases (tuberculosis, leprosy, beryllium dis-
ease, ulcerative colitis, or Crohn disease) [26–30]. Here,
the BTNL2 rs2076530 splice variant could not distinguish
sporadic from familial forms and we still have to under-
stand pathways through which the truncated form of
BTNL2 may be involved in the pathogenesis of sarcoidosis.
Sarcoidosis seems to be a multifactorial disease that
involves various genetic and environmental pathogenic
factors. To date, strong roles are suggested for different
SNPs in various genes mostly identified by association
studies: HLA-DP subregion, BTNL2, Annexin A11, and,
more recently Toll-like receptors, coiled-coil domain-
containing protein 88B, Ataxin-2/SH2B adapter protein
3, interleukin IL12B, and Beta-mannosidase/Nuclear fac-
tor NF-kappa-B p105 subunit [8, 31–36]. More than ten
genes might then be involved in the predisposition to
sarcoidosis and next generation sequencing studies will
probably provide new candidates for the molecular path-
ways of granuloma generation. Finally, sarcoidosis might
not be a single disease entity but rather a reaction to
various triggering events.
Because the present study data were collected from
both prevalent and incident cases (to increase the num-
ber of familial cases and recoverable DNAs), two biases
may be considered. Firstly, some data were missing
because of their retrospective collection and others be-
cause the 28 centres might not have given the same
number of visits or the same delays between visits to all
patients. Secondly, ancestry data relied on the ancestors’
birth countries and several patients had ancestors from
distinct continents. However, BTNL2 polymorphism was
shown linked to sarcoidosis regardless of ethnicity in
Caucasian, Afro-American, and Japanese patients [37].
Lastly, we did not use the clinical outcome status (COS)
of the WASOG Task Force [7] because the COS became
available four years after the start of the present study.
Conclusions
This study is an original comparison of sarcoidosis pheno-
types and genotypes between familial and sporadic cases in
a very large cohort. Despite a significant difference in
BTNL2 polymorphism between sarcoid patients and con-
trols, the lack of correlations between polymorphism, inher-
itance, clinical phenotypes, and outcome argues against the
consideration of this single genetic difference as a practical
marker for patient classification or optimized individual
patient management.
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